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Monocytes and Tissue Factor Promote Thrombosis in a Murine Model of
Oxygen Deprivation
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Clinical conditions associated with local or systemic hypox-
emia can lead to prothrombotic diatheses. This study was
undertaken to establish a model of whole-animal hypoxia
wherein oxygen deprivation by itself would be sufficient to
trigger tissue thrombosis. Furthermore, this model was used
to test the hypothesis that hypoxia-induced mononuclear
phagocyte (MP) recruitment and tissue factor (TF) expres-
sion may trigger the local deposition of fibrin which occurs
in response to oxygen deprivation. Using an environmental
chamber in which inhaled oxygen tension was lowered to
6%, hypoxic induction of thrombosis was demonstrated in





munohistologic evidence of fibrin formation in hypoxic lung
tissue using an antifibrin antibody, confirmed by 22.5-nm





revealing fibrin gamma–gamma chain dimers in lungs from














In-labeled platelets in the lung tissue of hypoxic compared









fibrinogen accumulation in animals which had either been
treated with hirudin or depleted of platelets before hypoxic
exposure. Because immunohistochemical analysis of hy-
poxic pulmonary tissue revealed strong MP staining for TF,





In-labeled murine MPs accumulated in hypoxic
pulmonary tissue, we evaluated whether recruited MPs
might be responsible for initiation of hypoxia-induced





) MP depletion before hypoxia reduced










) isolated murine MPs demonstrated in-





) administration of an anti–rabbit TF antibody that cross-





mulation and cross-linked fibrin accumulation in response
to hypoxia in vivo. In summary, these studies using a novel
in vivo model suggest that MP accumulation and TF ex-


























Venous thromboembolism is a major cause of morbidity and
mortality, and is associated with major trauma, orthopedic sur-
gery, and limb immobilization (1, 2). Lower-extremity venous
thrombosis may result in chronic venous insufficiency and is
also the precursor of pulmonary embolism that results in
50,000 to 100,000 deaths per year (3). Stasis of blood contrib-
utes to thrombi under these conditions, and thrombus forma-
tion has been localized to the parietal aspect of venous valve
cusps where depositions of platelets, leukocytes, and fibrin-
like material have been described (4). Severe hypoxemia has
been recorded at this same anatomic site within 2 h in a canine
limb immobilization model (5), and hypoxia has been impli-
cated in the derangement of vascular endothelial anticoagulant
properties (6).
Given these associations between hypoxia and thrombosis,
we hypothesized that reduced oxygen states might alter the
balance of anticoagulant/procoagulant mechanisms in the vas-
culature to favor activation of coagulation. Although most
thrombosis models rely on vascular injury to provide a nidus
for clotting (7–9), we have focused on how hypoxia per se may
modulate properties of cells of the vascular wall to promote
thrombus formation. In this study, we report an in vivo model
of whole animal hypoxia, in which hypoxia promotes fibrin
formation in the pulmonary vasculature. Our investigation
into mechanisms by which hypoxia may trigger thrombosis was





 accumulated in the lungs during hypoxic exposure, and
were associated with the production of tissue factor (TF).
Studies were undertaken to examine the possibility that MP
accumulation and TF expression underlie the initiation of hy-
poxia-induced thrombosis. These experiments provide a model
for the study of hypoxia-mediated thrombosis, and suggest
that MP recruitment and local TF expression are important
early events in the prothrombotic diathesis associated with ox-
ygen deprivation.
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In experiments approved by the Columbia
University Institutional Animal Care and Use Committee, CD-1 mice
(12–15 wk-old; Charles River Laboratories, Wilmington, MA) were
subjected to normobaric hypoxic conditions created by the regulated
addition of nitrogen to a chamber equipped with circulating fans, car-
bon dioxide, and ammonia elimination systems, and an on-line oxy-
gen sensor (Horiba Ltd., Kyoto, Japan). The environment within the
chamber (including temperature and humidity) was regulated by a




K Interface Inc., New York) which used




K Interface Inc.) running on
an XT clone microprocessor equipped with a logic board (model
Megaboard; Display Telecommunications Corp., Dallas, TX) and an
analogue to digital conversion package (LabMaster Scientific Solu-
tions Inc., Solon, OH). Mice were placed in the chamber in their
usual cages and allowed free access to food and water, and the system
parameters were adjusted to a final oxygen concentration of 5.5–
6.5%. Mice exposed to hypoxia were observed to be tachypneic and
have reduced activity, compared with normoxic counterparts. They
were exposed to hypoxia for varying times, killed, and tissue was har-
vested for further analysis. In studies to delineate fibrin formation in
lung vasculature, mice received intravenous heparin (10 U/g, result-




 300 s) immediately before killing to limit postmor-
tem clotting. Normoxic control animals (not placed in the chamber)




Mice were exposed to hypoxia or normoxia





tions, washed with PBS, pH 7.0, to remove blood, fixed in formalin,
and embedded in paraffin. Sections were stained with a rabbit antibody
raised to rat fibrin monomer which is reactive to fibrin and fibrinogen




g/ml, provided by Dr. Jef Emeis, Gabius In-
stitute, The Netherlands) (10). Sites of primary antibody binding
were visualized with a peroxidase-conjugated secondary antibody,




Mouse lung tissue was fixed in 2.5% glu-
taraldehyde and sections stained with uranyl acetate and lead. Trans-
mission electron microscopy was performed using a Jeol 100 CX-2




Lung tissue, harvested as above, was placed in
buffer (Tris, 0.05 M, NaCl, 0.15 M, heparin, 500 U/ml, final pH 7.6) on
ice and homogenized (Brinkmann Instruments, Inc., Westbury, NY).
Plasmin digestion was performed by a modification of the methods of
Francis (11). Human plasmin (0.32 U/ml, Sigma Chemical Co.) was




C for 6 h.
More plasmin (0.32 U/ml) was then added, and samples were agitated





15 min and the supernatant aspirated. As a positive control, mouse fi-
brinogen (2.5 mg in 0.25 ml; Sigma Chemical Co.) was clotted with
human thrombin (4 U; Sigma Chemical Co.) in tris-buffered saline
(1.75 ml) in the presence of calcium chloride (0.013 ml of 2.5 M) for 4 h
at room temperature. Clotted fibrinogen was lyophilized, ground into










tional plasmin (0.32 U/ml) was added after 6 h and samples were agi-
tated for an additional 2 h, after which no visible thrombus was
present. As a negative control, unclotted mouse fibrinogen was pro-
cessed in an identical manner. Samples of plasmin-treated hypoxic




g), and plasmin-treated clot-




g) were boiled in reducing SDS-
sample buffer for 5 min, and subjected to SDS-PAGE (10%; re-
duced). Samples were electrophoretically transferred to nitrocellulose,
and blots were reacted with a polyclonal rabbit anti–human antibody
prepared to gamma–gamma chain dimers present in cross-linked fibrin
(12) followed by horseradish peroxidase-conjugated goat anti–rabbit
IgG (Sigma Chemical Co.). Final detection of bands was performed
using the enhanced chemiluminescent Western blotting system (Am-
ersham International, Buckinghamshire, England). Optical density of
 
bands was determined by scanning radiograms with a ScanJet IICX
(Hewlett-Packard Co., Palo Alto, CA), linked to a Macintosh 8500
computer (Apple Computer, Inc., Cupertino, CA), with subsequent
analysis using NIH Image software.
 
Accumulation of radioiodinated fibrinogen and IgG in the lung.
 
Mouse fibrinogen or mouse nonimmune IgG (Sigma Chemical Co.)




I (DuPont NEN, Boston, MA) using the Iodo-
bead method (Pierce Chemical Co., Rockford, IL). The specific ra-













 95% precipitable in 10% trichloroacetic acid. Animals re-













Ci in 0.2 ml saline) via the tail vein. Experiments
with hypoxic and normoxic mice, or with hypoxic experimental and
hypoxic control mice, were conducted simultaneously using the same
batch of labeled protein. At the conclusion of the experiments, mice
were treated with heparin, immediately killed, and lungs were har-
vested, washed, dried, weighed, and assessed for tissue-associated ra-
dioactivity. Where indicated, mice were treated with hirudin (13) (0.5
mg/kg per h dissolved in saline) or saline alone delivered subcutane-
ously via osmotic pumps (Alza Corp., Palo Alto, CA) for 8 h before




I-fibrinogen followed by hypoxic ex-
posure. The thrombin time (13) in hirudin-treated animals was deter-
mined using a kit purchased from Sigma Chemical Co.
 
Isolation and labeling of mouse platelets, neutrophils (PMNs), and
MPs.
 
To assess deposition of platelets, PMNs, and MPs in hypoxic
versus normoxic lung, cell populations were isolated, radiolabeled,
and infused into mice as follows below.
Platelets were isolated as described (14). In brief, mouse blood
obtained by direct cardiac puncture was anticoagulated with 3.7% so-





min to obtain platelet-rich plasma, which was then washed three












) were resuspended in 1 ml of PBS and incubated under constant








In-oxine (Amersham Mediphysics Corp.,




C. After labeling, platelets
were washed three times with PBS and resuspended in saline; each








Ci in 0.2 ml) at the start of each experiment, with mice exposed to
normoxia or hypoxia. At the indicated time points, mice were treated
with heparin, killed, lungs were harvested, washed, dried and specific
activity determined (expressed as cpm/g dry tissue weight).
PMNs and MPs were isolated from mouse blood obtained by di-
rect cardiac puncture in anesthetized mice and anticoagulated with










Ficoll-Hypaque (Pharmacia Biotech, Piscataway, NJ) at room tem-
perature for 20 min. After hypotonic lysis of residual erythrocytes





 95% homogeneous cell population) were suspended
































C for 15 min under constant agitation. The suspension was cen-




 for 5 min and the pellet washed twice with HBSS/A,




 for 5 min. The washed PMN pellet was re-




















PMNs by tail vein injection at the start of experiments. MPs were iso-
lated by density gradient centrifugation as follows. Citrated mouse




1 with NaCl (0.9%) and 3 ml of this diluted blood
was added to an equal volume of Histopaque 1077 (Sigma Chemical




 for 30 min. The layer of mononuclear cells





 for 10 min. Cell pellets were resuspended in 3 ml RPMI 1640
medium containing 10% FBS (GIBCO, Grand Island, NY) and
plated on 35-mm culture dishes (Becton Dickinson Labware, Lincoln




C for 4 h. After washing twice
















































 MPs by tail vein injection at the start of experi-
ments. At the indicated time points, mice were treated with heparin,
killed, lungs were harvested, and tissue was processed as described
for platelets.
 
Depletion of platelets, PMNs, and MPs.
 
To determine the role of
platelets, PMNs and MPs in fibrin formation in hypoxic mouse lung,
the effect of antibody-induced depletion of each of these cell types









I-fibrinogen as described above. The complement activity of anti-
body-treated animals was compared with standard complement sera
by lysis of antibody-sensitized sheep red blood cells using reagents
purchased from Sigma Chemical Co.
Platelet depletion was accomplished by administering by tail vein
0.1 ml of either rabbit anti–murine platelet or control sera (Accurate
Chemical and Science Corp., Westbury, NY). Platelet counts 16 h af-













l.) Treatment with control sera resulted in no change in
platelet count.
MP or PMN depletion was accomplished using either rabbit anti-
murine MP or antimurine PMN sera (Accurate Chemical and Science
Corp.) (16, 17). Animals received daily intraperitoneal injections (0.3 ml)
for 3 d. Wright Giemsa–stained peripheral blood smears of anti-MP





culating MPs; anti-PMN antibody-treated animals displayed absence of
PMNs. In contrast, MPs and PMNs were unaffected in control animals.
 
Expression of TF, and in vitro and in vivo inhibition of TF activity.
 
TF expression was detected in isolated murine MPs and in hypoxic
murine lung by immunostaining, and in lung by Northern blotting. To
establish that the anti–rabbit TF IgG (18) used for immunostaining
blocked tissue factor functional activity, its ability to prolong the pro-
thrombin time (PT) of mouse plasma was assessed. In vivo experi-
ments were then conducted to assess the impact of the antibody on





Northern analysis of normoxic and hypoxic mouse lung RNA for
TF was performed by first isolating total RNA using the RNA STAT-
60 procedure (Tel-Test Inc., Friendswood, TX). RNA was subjected
to electrophoresis on 0.8% agarose gels, transferred to nitrocellulose,














-actin were labeled using ran-
dom primer labeling (Stratagene Inc., La Jolla, CA). To semiquanti-
tatively assess the strength of the TF bands, the NIH Image computer
program was used. Optical density of the TF bands was determined
by scanning the radiogram with a Hewlett Packard ScanJet IICX
linked to a Macintosh 8500 computer (Hewlett Packard Co., Apple
Computer, Inc.), with subsequent analysis using NIH Image software.
Immunoblotting for TF antigen was performed using affinity-
purified goat IgG against rabbit TF apoprotein (18) (generously pro-
vided by Dr. L.V.M. Rao). The ability of the antibody to cross-react
with mouse and rabbit TF apoprotein was assessed by immunoblot-
ting mouse and rabbit brain thromboplastin. Mouse brain thrombo-
plastin was prepared using a modification of the method of Broze
(20): the brains from five killed mice were homogenized in 40 ml of
ice cold acetone; the slurry was filtered through No. 50 filter paper,
dried, and washed in cold acetone and filtered four more times; after
drying overnight, the residual powder was suspended in normal sa-

















used in subsequent assays. Rabbit brain thromboplastin was pur-




g of each thromboplastin prep-
aration was subjected to SDS-PAGE (10% gel), transferred to nitro-









C after blocking with 8% milk protein for 2 h at room tempera-
ture. After washing in PBS with 0.1% Tween 20, peroxidase-con-





cal Co.) was added. Final bands were detected on x-ray film using
the enhanced chemiluminescent system (Amersham International).
Immunohistology for TF antigen was performed using the goat
IgG against rabbit TF on lung tissue from normoxic or hypoxic ani-
mals, with an alkaline phosphatase-conjugated rabbit anti–goat sec-
ondary antibody (Sigma Chemical Co.). As a positive control for TF,
immunohistochemistry was performed on paraffin-embedded sec-
tions of epidermis from normal mice. To determine immunostaining
specificity, blocking of goat anti–rabbit TF IgG was accomplished by


















g/ml]). To confirm the identity
of the cells expressing TF, a dual-labeling procedure was employed
(21). In this technique, the section was first immunostained with an
antibody against the MP antigen, F4/80 (a rat anti–mouse monoclonal
antibody (22) (Caltag Laboratories, So. San Francisco, CA) and de-
veloped with an alkaline phosphatase-conjugated anti–rat secondary
antibody (Sigma Chemical Co.) and photographed. After decoloriza-
tion, immunostaining for TF was performed using the goat IgG against
rabbit TF with a horseradish peroxidase-conjugated anti–goat second-
ary antibody (Sigma Chemical Co.), and the section rephotographed.
This technique allows side-by-side comparison of the same tissue sec-
tion.
Murine MPs were isolated from 12 ml of blood as described pre-
viously and resuspended in 16 ml of RPMI 1640 medium containing





C on 4 Permanox chamber slide two-well culture chambers
(Nunc, Inc., Naperville, IL) and washed three times with PBS to re-
move nonadherent cells. Serum-free RPMI was then added to the
culture chambers and cells were quiescent for 24 h. Cells were then




16 mmHg) for 16 h, washed with HBSS, and fixed with formalin.
Cells were stained with anti–rabbit TF IgG, with sites of primary an-
tibody binding visualized with an alkaline phosphatase-conjugated
rabbit anti–goat secondary antibody (Sigma Chemical Co.). To
identify the adherent cells as MPs, immunostaining for F4/80 anti-
gen was performed using the rat anti–mouse monoclonal antibody
(Caltag Laboratories) and a horseradish peroxidase-conjugated sec-
ondary antibody (Sigma Chemical Co.).
In vitro inhibition of TF procoagulant activity using the goat anti–
rabbit TF IgG was assessed by the prothrombin time assay (PT;
Sigma Chemical Co.). A standard clotting curve was constructed as
follows: mouse brain thromboplastin was serially diluted with normal
saline, mixed with an equal volume of 0.02 M calcium chloride (Dade
Division, Baxter Corp., Miami, FL) and added to half the volume of
citrated mouse plasma, and the time to thrombus formation was mea-




C. A 72-fold protein excess of
either goat anti–rabbit TF IgG or goat nonimmune IgG was preincu-





PT was measured. The amount that the clotting time was changed by
the addition of anti-TF IgG or nonimmune IgG was converted to per-
centage of TF activity from the standard curve, with 100% TF activity
representing the PT without addition of IgG.
In vivo inhibition of TF using goat anti–rabbit TF IgG was as-
sessed by pretreatment of mice (by tail vein injection) with 150 mg/kg
of either goat anti–rabbit TF IgG or goat nonimmune IgG (control),
given 2 h before 16 h of hypoxic exposure. Tissue was then harvested




I-fibrin/fibrinogen deposition and cross-linked fi-









SEM for ratios calculated as described by Cochran (23). Statistical





for comparisons between two groups, using Statview software (Aba-


















Deposition of fibrin, radioiodinated fibrin/fibrinogen, and plate-
lets in hypoxic pulmonary vasculature.
 
Tissue fibrin deposition
induced by hypoxic exposure was first demonstrated by immu-
nohistochemistry using a rabbit antibody raised to rat fibrin
monomer (10). Staining performed on freshly isolated lung tis-
sue (with antemortem heparin administration to limit post-
mortem clotting) demonstrated intravascular fibrin deposition
as early as 4 h that became especially evident by 8 h in hypoxic









Electron microscopy was performed to confirm the presence
of fibrin; platelet-associated fibrin demonstrated the charac-









Immunoblots of lung tissue extracts were then performed
to provide additional confirmation of hypoxia-induced thrombo-
sis. These studies used antibody raised to the gamma–gamma
chain dimer present in cross-linked fibrin (12). Extracts of lung
Figure 1. Fibrin deposition 
in pulmonary vasculature 
from mice exposed to hy-
poxia or normoxia. Mice 
were exposed to hypoxia 
(A), FiO2 of z 6%, or main-
tained in normoxia (B) for
8 h, followed by administra-
tion of heparin before kill-
ing. Tissue was immuno-
stained with antifibrin 
antibody. A and B, 3600; 
(L) vascular lumen; (arrows) 
vascular endothelium; *red 
blood cells. Experiments 
with the same concentration 
of nonimmune serum dem-
onstrated no staining (data 
not shown). Electron micro-
graph of hypoxic (16 h) mu-
rine pulmonary vasculature 
(C) showing endothelium, 
red blood cells (RBC), plate-
let clumping (Plt), and plate-
let-associated fibrin (arrow). 
Higher magnification (D) 
demonstrates 22.5-nm peri-
odicity characteristic of fi-
brin; black bar, 112 nm.
C, 312,450; D, 344,650.
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were digested with plasmin, and the digest applied to reduced
SDS-PAGE. As a positive control for fibrin, murine fibrino-
gen clotted in vitro and digested by plasmin displayed a simi-
larly migrating band to the hypoxic lung digests (Fig. 2). Densi-
tometric analysis comparing the known amount of fibrin
loaded in the fibrin lane with that in hypoxia lane reveals that
z 1.2 mg of fibrin are present per mg of hypoxic lung tissue. In
contrast, plasmin digests of unclotted fibrinogen or normoxic
mouse lung demonstrated no discernible bands (Fig. 2, fibrino-
gen or normoxia lanes, respectively).
As a more rapid and semiquantitative assay for fibrin depo-
sition in hypoxic lung in vivo, accumulation of 125I-fibrin/fibrin-
ogen was studied. For these experiments, 125I-fibrinogen or
125I-IgG (control protein) was injected into mice, after which they
were randomly separated into normoxic or hypoxic exposure
groups for the indicated durations. Accumulation of 125I-IgG
was not different between hypoxic and normoxic tissue up to
16 h (Fig. 3), though at longer times (24 h and beyond, data not
shown) there was an increase in IgG deposition, consistent with
increased vascular permeability on prolonged exposure to oxy-
gen deprivation (25). In contrast, there was a steady rise in
125I-fibrin/fibrinogen in the hypoxic lung versus normoxic con-
trols (Fig. 3; cpm/g in hypoxic/normoxic lung tissue at 1, 4, 8,
and 16 h, respectively, were 5.0 3 10466.6 3 103/4.5 3 10463.7 3
103, 5.8 3 10467.2 3 103/4.2 3 10461.2 3 104, 3.2 3 10462.1 3
103/1.7 3 10462.1 3 103, 2.8 3 10462.3 3 103/7.7 3 10367.3 3
102, respectively). In addition, 111In-labeled platelets accumu-
lated in hypoxic lung in a time-dependent manner versus nor-
moxic controls (Fig. 4; cpm/g in hypoxic and normoxic lung at
2, 4, 8, and 16 h, respectively, were 2.2 3 10462.5 3 103/1.8 3
10464.8 3 102, 2.4 3 10461.2 3 103/1.5 3 10462.0 3 103, 1.1 3
10461.1 3 103/7.3 3 10465.5 3 102, 1.8 3 10461.1 3 103/9.3 3
10361.7 3 103, respectively).
Further evidence confirming that activation of coagulation
was responsible for accumulation of 125I-fibrin/fibrinogen and
cross-linked fibrin in hypoxic murine lung was derived from
studies with the thrombin inhibitor hirudin (13). Mice pre-
treated with hirudin at a dose which increased thrombin time
from 18 to 50 s demonstrated inhibition of hypoxic 125I-fibrin/
fibrinogen deposition (Fig. 5 A) and a decrease in the Western
blotting signal for fibrin gamma–gamma dimer (Fig. 5 B). To
evaluate whether platelets, which provide a major amplifica-
tion mechanism for activation of the procoagulant pathway,
also participate in hypoxia-induced thrombosis, the effect of
platelet depletion on hypoxia-induced 125I-fibrin/fibrinogen ac-
cumulation was examined. Platelet depletion reduced pulmo-
nary 125I-fibrin/fibrinogen accumulation (Fig. 5 A).
Involvement of PMNs and MPs in hypoxia-induced accu-
mulation of radioiodinated fibrin/fibrinogen in hypoxic lung.
To explore potential mechanisms which might initiate hy-
poxia-induced thrombosis, we examined the roles of other cir-
culating cell types in addition to platelets. For these studies, we
used a strategy of depleting certain cell populations and exam-
Figure 2. Immunoblotting of 
lung extracts with antibody to 
fibrin gamma–gamma chain 
dimers. Mice were exposed to 
normoxia (n 5 4) or hypoxia 
(n 5 4) for 16 h and heparin 
was administered immediately 
before killing to prevent post-
mortem thrombosis. Lung tis-
sue was harvested, washed, ho-
mogenized, treated with plasmin as described in the text, and samples 
were pooled. Other samples consisted of mouse fibrinogen or fibrin, 
also treated with plasmin. Samples were then solubilized in reducing 
sample buffer and subjected to reduced SDS-PAGE, transferred to 
nitrocellulose and immunoblotted with antibody to fibrin gamma–
gamma chain dimers.
Figure 3. Accumulation of 125I-fibrin/fibrinogen in hypoxic lung. 
Mice were injected via tail vein with either 125I-fibrinogen (n 5 32) or 
125I-nonimmune IgG (n 5 29), killed at the indicated times after ex-
posure to hypoxia or normoxia, and lung tissue was processed as de-
scribed in the text. Hypoxic and normoxic animals at each time point 
received identical amounts of the labeled protein. Data are graphed 
as the percent of normoxic control which is the ratio of cpm/g dry tis-
sue in hypoxic versus normoxic animals (100% 5 same amount of ra-
dioactivity in hypoxic and normoxic tissue per g). **P , 0.01 for hy-
poxic versus normoxic cpm/g.
Figure 4. Deposition of 111In-labeled cells in hypoxic lung. Mice were 
injected via tail vein with either 111In-labeled murine platelets (n 5 
36) or MPs (n 5 22), and killed at the indicated times after exposure 
to hypoxia or normoxia. Lung tissue was processed as described in 
the text. Hypoxic and normoxic animals at each time point received 
identical amounts of the labeled cells. Data are graphed as the per-
cent of normoxic control which is the ratio of cpm/g dry tissue in hy-
poxic versus normoxic animals (100% 5 same amount of radioactiv-
ity in hypoxic and normoxic tissue per g). *P , 0.05 and **P , 0.01 
for hypoxic versus normoxic cpm/g.
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ining the impact on hypoxic 125I-fibrin/fibrinogen deposition.
Because of previous studies indicating that hypoxia promotes
tissue leukostasis (26), probably through multiple mechanisms,
we considered the possibility that PMNs drawn into hypoxic
lung might become activated, damage the endothelium, and
expose underlying TF. 111In-labeled PMN accumulation signif-
icantly increased in hypoxic lung compared with normoxic
controls at 8 and 16 h (225630%, 500650%, respectively; n 5
19, P , 0.01 for each time point). Although mice were ren-
dered profoundly neutropenic before hypoxic exposure (plate-
lets and MPs were not reduced on peripheral blood smear),
hypoxia-induced 125I-fibrin/fibrinogen accumulation in lung re-
mained unaltered (Fig. 5 A).
MPs have the potential to express TF, suggesting that they
may play a role in thrombotic processes (27, 28). Murine MPs
labeled with 111In were arrested in hypoxic lung, compared
with normoxic counterparts (Fig. 4), as early as 2 h after the
initiation of hypoxic exposure. The possible contribution of
MPs to 125I-fibrin/fibrinogen deposition and cross-linked fibrin
formation in hypoxic lung was suggested by studies in which
MPs were depleted before hypoxic exposure (peripheral blood
smears confirmed , 1% MPs after antibody administration)
(16). In MP-depleted animals, hypoxic deposition of 125I-fibrin/
fibrinogen and Western blot fibrin gamma–gamma dimer sig-
nal were reduced 35 and 65%, respectively (Fig. 5, A and B).
Expression of TF in hypoxic lung and by hypoxic MPs.
Because the data suggested that MPs participate in hypoxia-
induced thrombosis, and because MPs are a known source of
TF (27, 28), we investigated whether hypoxia could trigger TF
expression in MPs in vitro or in the lung in vivo.
The ability of goat anti–rabbit TF IgG (18) to cross-react
with murine TF established suitability of using this antibody in
a murine system. Immunoblotting with mouse brain thrombo-
plastin and rabbit brain thromboplastin preparations (sources
of TF) demonstrated comigrating bands of similar molecular
weights (18, 19, 29; Fig. 6 A). Mouse epidermis, normally high
in TF, exhibited an intense signal when goat anti–rabbit TF
IgG was used for immunostaining (Fig. 6 B); the signal was
markedly diminished by preincubating the antibody with puri-
fied rabbit TF (Fig. 6 C). The ability of goat anti–rabbit TF
IgG to block TF procoagulant activity was assessed using the
prothrombin time, a measure of TF-dependent clotting. Prein-
cubation of murine thromboplastin with goat anti–rabbit TF
IgG resulted in prolongation of the PT equal to a 70% reduc-
tion in TF activity (Fig. 6 D).
Next, expression of TF was studied in lung harvested from
hypoxic mice. Northern analysis demonstrated a 4.7-fold in-
crease in TF RNA, quantified with NIH Image software,
whereas b-actin transcripts were unchanged, after 4 h of hy-
poxia (Fig. 7 A). Immunostaining using goat anti–rabbit TF
IgG showed enhanced antigen expression in hypoxic murine
lung, compared with normoxic controls (Fig. 7, B and C). In-
creased TF staining in hypoxic lung (Fig. 7 E) occurred in cells
staining for the MP antigen, F4/80 (Fig. 7 D). In addition, ani-
mals made deficient in circulating monocytes displayed less
pulmonary TF expression than controls (data not shown). To
confirm that murine MPs increase expression of TF when de-
prived of oxygen, MPs isolated from murine blood (staining
for F4/80 antigen; Fig. 7 H) and exposed to hypoxia showed
enhanced TF immunostaining (Fig. 7 G) compared with nor-
moxic MPs (Fig. 7 F). Having established that goat anti–rabbit
TF IgG has functional in vitro TF blocking ability (Fig. 7 D),
we used it to investigate hypoxia-induced thrombosis in vivo,
as measured by 125I-fibrin/fibrinogen deposition and cross-
linked fibrin formation in hypoxic lung. Mice pretreated be-
fore hypoxic exposure with goat anti–rabbit TF IgG, but not
nonimmune IgG, had a 39% suppression of 125I-fibrin/fibrino-
gen accumulation (Fig. 5 A) and a 95% reduction of the fibrin
gamma–gamma dimer signal by Western blot (Fig. 5 B). Addi-
tional studies demonstrated the half-life of elimination of
125I-labeled anti-TF IgG in mice to be z 53 h, consistent with
previous measurements of IgG injected into mice (30).
Discussion
In the 1850s, Virchow linked venous thrombosis to hypercoag-
ulability, vascular damage, and stasis (31). In recent years,
nonpulsatile flow resulting in stasis has been associated with
rapid intravascular hypoxemia, white blood cell margination,
and thrombus formation in veins of the lower extremities (4, 5).
Figure 5. The effects of pre-
treatment regimens on pulmo-
nary fibrin deposition. (A) The 
effects of hirudin, cell deple-
tion, or TF inhibition on pul-
monary deposition of
125I-fibrin/fibrinogen (125I-Fib) 
after hypoxic exposure (16 h); 
experimental and control ani-
mals in each group received 
identical amounts of
125I-fibrinogen. In the hirudin 
experiments (n 5 13), mice re-
ceived hirudin or saline (con-
trol group). Either platelets 
(Plt), PMNs, or MPs were de-
pleted (2) with specific anti-
sera, with controls receiving the identical dose of nonimmune sera
(n 5 9, 8, and 8, for Plt, PMN, and MP experiments, respectively). TF 
was inhibited by goat anti–rabbit TF IgG (Anti-TF IgG) administra-
tion, with control animals receiving goat nonimmune IgG (Nonim-
mune IgG; n 5 11 for TF inhibition experiments). Data are graphed 
as the percent of control which is the ratio of cpm/g dry tissue in 
treated versus control animals. *P , 0.05 and **P , 0.01 for treated 
versus control cpm/g. (B) Using identical pretreatment regimens as in 
the 125I-fibrin/fibrinogen experiments above, the presence of fibrin 
gamma–gamma chain dimers was assessed in animals treated with 
hirudin, anti-TF antibody (Anti-TF IgG), or depleted of MPs (with 
nonimmune sera serving as a control). The figure shows blotting from 
a representative animal in each treatment group.
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These observations, taken together with our previous findings
that hypoxia decreased expression of the anticoagulant cofac-
tor thrombomodulin (6), suggested that oxygen deprivation
per se might result in a prothrombotic diathesis. In view of the
continuing clinical importance of venous thromboembolism,
especially in certain high-risk patients (1), we sought to de-
velop an in vivo model allowing investigation of pathophysio-
logic mechanisms underlying hypoxia-associated thrombosis.
At the outset, we speculated that hypoxia would modulate
endothelial properties directly, promoting development of the
prothrombotic state. Shatos et al. (32) observed changes in ex-
pression of fibrinolytic components. However, in those experi-
ments with ECs, the small increase in plasminogen activator
inhibitor-1 and plasminogen activators did not appear to be
potent factors promoting fibrin deposition. Similarly, our ear-
lier experiments demonstrating hypoxic suppression of endo-
thelial thrombomodulin at the mRNA, antigen, and activity
levels, occurred only after 24 h, whereas fibrin deposition in
this study was observed within 4–8 h. Further experiments with
hypoxic ECs failed to show induction of TF, though at later
times, activation of Factor X (independent of TF) was ob-
served (6). Because ECs exposed to hypoxia express P-selectin
Figure 6. Cross-reactivity of goat anti–rabbit TF IgG. (A) Cross-reac-
tivity of the goat anti–rabbit TF IgG for murine and rabbit TF is dem-
onstrated by comigrating bands of similar molecular weights for mouse 
(M) and rabbit (R) brain thromboplastin. Preincubation of anti–rabbit 
TF IgG with purified rabbit TF blocked visualization of the bands 
(data not shown). (B) TF in murine epidermis (Epid) is visualized by 
immunostaining (red) with goat anti–rabbit TF IgG. No staining was 
seen using goat nonimmune IgG (data not shown). (C) Blocking was 
achieved by preincubation with purified rabbit TF. (D) The ability of 
goat anti–rabbit TF IgG (Anti-TF IgG) to inhibit in vitro TF-depen-
dent coagulation, as assessed by prolongation of the prothrombin 
time, was compared to the effect of goat nonimmune IgG (Nonim-
mune IgG). Data are graphed as percent of TF activity, with 100% ac-
tivity representing the baseline PT. **P , 0.01 for Anti-TF IgG versus 
Nonimmune IgG percentage of TF activity. B, C 3200.
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(33), IL-8 (26), synthesize platelet-activating factor (PAF)
(34), and express intercellular adhesion molecule-1 (ICAM-1)
(34) resulting in enhanced adhesivity of hypoxic endothelium
for leukocytes and subsequent PMN activation (34), we first
investigated whether PMN recruitment might underlie hy-
poxia-induced thrombosis. Experimental data in our model
showed that 111In-labeled PMNs deposited in hypoxic lung, but
that 125I-fibrin/fibrinogen accumulation was not affected in
Figure 7. Expression of tissue factor 
during hypoxia. (A) Northern blot-
ting was performed using 32P-labeled 
cDNA probes for murine TF or 
b-actin on lung RNA from mice ex-
posed to normoxia (n 5 4, lane 1) or 
4 h of hypoxia (n 5 4, lane 2); a 4.7-
fold increase in TF RNA was quanti-
fied using NIH Image software. Lung 
tissue from normoxic mice (B) and 
mice hypoxic for 6 h (C) was simulta-
neously immunostained with goat 
anti–rabbit TF IgG, with TF (pink
areas) being more prominent in hy-
poxic lung. To identify cells staining 
for TF, hypoxic lung was first immu-
nostained for the MP antigen F4/80 
(D; pink staining areas); the section 
was then decolorized and immu-
nostained for TF (E; reddish staining 
areas). F4/80 and TF occur on the 
same cells (D, E; arrows). Murine 
MPs were isolated from peripheral 
blood and exposed to 16 h of nor-
moxia (F) or hypoxia (G), and as-
sessed for TF expression with goat 
anti–rabbit TF IgG (red staining). 
Note the greater number of hypoxic 
MPs staining for TF (arrows). (H) 
Expression of the MP antigen, F4/80 
(brown staining), on hypoxic murine 
MPs. B, C, D, E, F, G, H, 3600.
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neutropenic mice. This suggested that accumulated PMNs were
unlikely to mediate early events in the pathogenesis of fibrin
deposition associated with oxygen deprivation.
In contrast to PMNs, however, MP recruitment appeared
to be involved in the pathogenesis of fibrin formation, as ani-
mals deficient in MPs exhibited reduced 125I-fibrin/fibrinogen
and cross-linked fibrin accumulation under hypoxic condi-
tions. Further studies showed that TF expression by recruited
MPs was likely to underlie initiation of hypoxia-induced fibrin
deposition. These data lead us to propose a scenario in which
MPs are recruited into hypoxic lung, become activated, and
express TF which promotes fibrin formation. Platelets also ac-
cumulate, amplifying the thrombotic process. In support of our
concept that MPs contribute to pathologic fibrin formation as-
sociated with hypoxia, we have also found that hypoxic MPs
also synthesize increased amounts of a key inhibitor of the fi-
brinolytic pathway, plasminogen activator inhibitor-1 (PAI-1)
(35). Monocyte regulation of coagulation in hypoxia is consis-
tent with previous data that suggest an active role for MPs in
other aspects of the physiologic/pathophysiologic response to
oxygen deprivation, such as elaboration of angiogenic factors
(36, 37). Whereas others have shown that TF plays an impor-
tant role in pulmonary fibrin deposition in response to injury
(38), in our model, hypoxia alone was a sufficient stimulus for
TF induction. Interference with hypoxic MP recruitment or TF
expression in vivo, either by decreasing the number of MPs, or
by blocking TF with anti-TF IgG, resulted in decreased throm-
bosis, as measured by hypoxia-induced 125I-fibrin/fibrinogen
and cross-linked fibrin accumulation. These data support ob-
servations demonstrating induction of TF in alveolar macro-
phages in lung subjected to ischemic preservation (39).
Although it is possible that our experimental method of
MP depletion (immunodepletion) may have affected more
than one cell type, this was not evident on peripheral smears.
In addition, complement activity in the MP- and PMN-depleted
animals was normal (data not shown). PMNs, though having
an identified role in platelet interaction (40), and accumulating
later on in hypoxic lung tissue in our experiments, do not ap-
pear to be involved in the initiation of hypoxia-induced throm-
bosis. The ability of hirudin, platelet or MP depletion, and
anti-TF antibody administration to only partially suppress
125I-fibrin/fibrinogen deposition, but more fully inhibit cross-
linked fibrin accumulation (measured by Western blotting for
gamma–gamma dimer) suggests that there is high background
signal present in the 125I-fibrin/fibrinogen assay. Distinguishing
intravascular from extravascular sites of thrombosis using
whole-lung assays (125I-fibrin/fibrinogen deposition and West-
ern blotting for gamma–gamma dimer) is complicated by the
potentially procoagulant environment of the alveolar space.
However, in the current experiments, immunohistology dem-
onstrates that there is intravascular fibrin formation in this
model.
One potential experimental limitation involves the need to
use living animals in this model of hypoxia-induced thrombo-
sis. As with any in vivo model, it is possible that oxygen depri-
vation might foster systemic cytokine activation, and enhanced
TF expression in circulating MPs as well as extravascular cells.
In the same light, MPs themselves could also indirectly induce
TF expression elsewhere in the lung through the elaboration
of mediators. Our results, therefore, may reflect both local and
systemic factors. To examine the effect of whole animal hy-
poxia on impaired intestinal barrier function (which could in-
crease systemic exposure to endotoxins and complicate local
findings of TF production), plasma from mice exposed to 16 h
of hypoxia (n 5 3) and normoxia (n 5 3) was assayed for en-
dotoxin by the Limulus amebocyte lysate method (41) (E-Tox-
ate; Sigma Chemical Co.). In both groups of mice, endotoxin
was undetectable, indicating that the duration and degree of
hypoxia used in these experiments did not result in endotox-
inemia within the detection limits of the assay (0.06 EU/ml).
This in vivo model of hypoxia-induced thrombosis might
constitute a useful method for evaluating transgenic and knock-
out mice with alterations in the coagulation system (42–44).
Our hypothesis to explain early fibrin formation in settings of
oxygen deprivation raises important questions concerning un-
derlying mechanisms. How are MPs recruited into hypoxic
loci? By what means does oxygen deprivation increase TF?
What other factors in hypoxic and ischemic microenviron-
ments prime the procoagulant pathway and/or suppress natu-
ral antithrombotic mechanisms? Answers to these questions
will provide critical tests of our hypothesis and provide new in-
sights to delineate hypoxia-inducible mechanisms promoting
fibrin formation in a range of ischemic conditions.
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